Historically, HER2-positive breast cancer has been associated with a more aggressive phenotype and worse prognosis than other subtypes [2,6,7]; however, HER2-targeted treatments have improved survival rates and reduced the risk of relapse in early-stage disease [8,9,10]. This evidence concerns the gene ERBB2 and breast carcinoma.